Q-omics provides the consensus-scored MFFP2 profile across patient tissues and cancer cell-line models. MFFP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MFFP2 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, MFFP2 RNA expression shows 7,691 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, LIHC, and LUAD as cancer lineages where MFFP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFFP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFFP2 survival associations across molecular data types. MFFP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFFP2 RNA expression–survival associations across cancer types. High MFFP2 expression shows unfavorable associations in MESO, LIHC, LUAD, ACC and STAD, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MFFP2 RNA expression.
This table summarizes MFFP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MFFP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFFP2 shows lower tumor expression in PAAD and higher tumor expression in LIHC, BLCA, COAD, STAD and LUAD. The LIHC box plot shows higher MFFP2 RNA expression in tumor versus normal tissue (log2 FC = +0.085, t-test p < 0.001).
This table shows molecular features associated with MFFP2 in patient tissues and cancer cell lines. In patient samples, MFFP2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MFFP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
